Skip to content

OS Therapies OSTX Income Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$22.4M+36.9%$16.36M+94.0%$8.43M+43.2%$5.89M+55.5%$3.79M+33.4%
$11.47M-7.1%$12.34M+9.7%$11.25M+20.3%$9.35M+26.4%$7.4M+86.1%
-$33.87M-18.0%-$28.71M-45.8%-$19.68M-29.1%-$15.24M-36.3%-$11.18M-64.1%
-$1.4M-2,807%-$48.14K-103%$1.4M+45.5%$962.08K+917%-$117.7K+94.3%
-$35.27M-22.7%-$28.75M-57.3%-$18.28M-28.0%-$14.28M-26.4%-$11.3M-27.2%
-$1.08-9.1%-$0.99+18.9%-$1.22-2.5%-$1.19+5.6%-$1.26+5.3%
-$33.39M-17.8%-$28.34M-45.8%-$19.44M-28.5%-$15.13M-35.3%-$11.18M-64.1%
-$33.87M-18.0%-$28.71M-45.8%-$19.68M-29.1%-$15.24M-36.3%-$11.18M-64.1%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is OS Therapies profitable?
OS Therapies is not currently profitable: it reported a net loss of $35.3M over the trailing twelve months.
What is OS Therapies's earnings per share?
OS Therapies's diluted EPS over the trailing twelve months is $-1.08.
Where does OS Therapies's income statement data come from?
Every line is extracted from OS Therapies's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.